Retinal implant offers rudimentary sight to blind

Article

Second Sight's "bionic eye" implant, the Argus II Retinal Prosthesis System, has been implanted into two blind patients at London's Moorfields Eye Hospital by Dr Lyndon da Cruz and team.

Second Sight's "bionic eye" implant, the Argus II Retinal Prosthesis System, has been implanted into two blind patients at London's Moorfields Eye Hospital by Dr Lyndon da Cruz and team. The patients were the first British subjects of a multinational Phase I clinical trial, being conducted in Britain, the US and Mexico.

The implant is designed to combat retinitis pigmentosa (RP). Sixty electrodes, which conduct information acquired from an external camera to the retina, provide a rudimentary form of sight (motion and light and dark) to implanted subjects. The first generation of the implant, the Argus 16, comprised 16 electrodes and was tested in six RP patients between 2002 and 2004; the next generation device, currently under development, will have 1000 electrodes, allowing facial recognition.

Four more subjects have been recruited into the US arm of the trial. If the trials go well, it is hoped that the implant will be widely available within five years.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.